Breaking News

Harlan CRS, Bertin Pharma Enter Strategic Pact

By Kristin Brooks | March 4, 2014

To offer comprehensive services for early drug development

Harlan Contract Research Services and Bertin Pharma, headquartered in Montigny-le-Bretonneux, France, have entered a strategic partnership to offer comprehensive services for early drug development. The companies will offer a wider range of drug discovery and translational medicine services, including expanded profiling and molecule testing, particularly in the context of regulatory studies. Harlan CRS will provide its drug discovery and translational medicine offerings using Bertin Pharma’s expertise in immunology and biomarkers.
 
“The new agreement benefits us both strategically and scientifically,” said Ciriaco Maraschiello, director of strategic initiatives and director of drug discovery and translational medicine at Harlan CRS. “Working together, we will provide the pharmaceutical industry the best team of scientists to increase the likelihood of success for new generation drugs.”
 
“For Bertin Pharma, this partnership will increase our international visibility and allow us to expand our services by integrating project management capabilities and expertise,” said Xavier Morge, managing director of Bertin Pharma.

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important